Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial - Aix-Marseille Université Access content directly
Journal Articles Lancet Oncology Year : 2016

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

Isabelle Ray-Coquard
Antoine Italiano
Emmanuelle Chauzit
  • Function : Author
Jean-Yves Blay

Domains

Cancer
No file

Dates and versions

hal-03623734 , version 1 (29-03-2022)

Identifiers

Cite

Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, et al.. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, 2016, 17 (5), pp.632-641. ⟨10.1016/s1470-2045(16)00075-9⟩. ⟨hal-03623734⟩
20 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More